Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy: Miniperspective

por Sonawane, Yogesh A., Taylor, Margaret A., Napoleon, John Victor, Rana, Sandeep, Contreras, Jacob I., Natarajan, Amarnath
Publicado 2016

Structure–Activity Relationship Studies with Tetrahydroquinoline Analogs as EPAC Inhibitors

por Sonawane, Yogesh A., Zhu, Yingmin, Garrison, Jered C., Ezell, Edward L., Zahid, Muhammad, Cheng, Xiaodong, Natarajan, Amarnath
Publicado 2017

Ferulic acid dimer as a non-opioid therapeutic for acute pain

por Priebe, Alaini, Hunke, Megan, Tonello, Raquel, Sonawane, Yogesh, Berta, Temugin, Natarajan, Amarnath, Bhuvanesh, Nattamai, Pattabiraman, Mahesh, Chandra, Surabhi
Publicado 2018

Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters Neurobehavior

por Umfress, Alan, Singh, Sarbjit, Ryan, Kevin J., Chakraborti, Ayanabha, Plattner, Florian, Sonawane, Yogesh, Mallareddy, Jayapal Reddy, Acosta, Edward P., Natarajan, Amarnath, Bibb, James A.
Publicado 2022

Discovery and characterization of small molecule Rac1 inhibitors

por Arnst, Jamie L., Hein, Ashley L., Taylor, Margaret A., Palermo, Nick Y., Contreras, Jacob I., Sonawane, Yogesh A., Wahl, Andrew O., Ouellette, Michel M., Natarajan, Amarnath, Yan, Ying
Publicado 2017

CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax

por Kour, Smit, Rana, Sandeep, Contreras, Jacob I., King, Hannah M., Robb, Caroline M., Sonawane, Yogesh A., Bendjennat, Mourad, Crawford, Ayrianne J., Barger, Carter J., Kizhake, Smitha, Luo, Xu, Hollingsworth, Michael A., Natarajan, Amarnath
Publicado 2019

Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy

por Robb, Caroline M., Kour, Smit, Contreras, Jacob I., Agarwal, Ekta, Barger, Carter J., Rana, Sandeep, Sonawane, Yogesh, Neilsen, Beth K., Taylor, Margaret, Kizhake, Smitha, Thakare, Rhishikesh N., Chowdhury, Sanjib, Wang, Jing, Black, Jennifer D., Hollingsworth, Michael A., Brattain, Michael G., Natarajan, Amarnath
Publicado 2017

Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy

por Robb, Caroline M., Kour, Smit, Contreras, Jacob I., Agarwal, Ekta, Barger, Carter J., Rana, Sandeep, Sonawane, Yogesh, Neilsen, Beth K., Taylor, Margaret, Kizhake, Smitha, Thakare, Rhishikesh N., Chowdhury, Sanjib, Wang, Jing, Black, Jennifer D., Hollingsworth, Michael A., Brattain, Michael G., Natarajan, Amarnath
Publicado 2020

Metabolic, Pharmacokinetic, and Activity Profile of the Liver Stage Antimalarial (RC-12)

por Dong, Yuxiang, Sonawane, Yogesh, Maher, Steven P., Zeeman, Anne-Marie, Chaumeau, Victor, Vantaux, Amélie, Cooper, Caitlin A., Chiu, Francis C. K., Ryan, Eileen, McLaren, Jenna, Chen, Gong, Wittlin, Sergio, Witkowski, Benoît, Nosten, François, Sriraghavan, Kamaraj, Kyle, Dennis E., Kocken, Clemens H. M., Charman, Susan A., Vennerstrom, Jonathan L.
Publicado 2022

Small-molecule IKKβ activation modulator (IKAM) targets MAP3K1 and inhibits pancreatic tumor growth

por Napoleon, John Victor, Sagar, Satish, Kubica, Sydney P., Boghean, Lidia, Kour, Smit, King, Hannah M., Sonawane, Yogesh A., Crawford, Ayrianne J., Gautam, Nagsen, Kizhake, Smitha, Bialk, Pawel A., Kmiec, Eric, Mallareddy, Jayapal Reddy, Patil, Prathamesh P., Rana, Sandeep, Singh, Sarbjit, Prahlad, Janani, Grandgenett, Paul M., Borgstahl, Gloria E. O., Ghosal, Gargi, Alnouti, Yazen, Hollingsworth, Michael A., Radhakrishnan, Prakash, Natarajan, Amarnath
Publicado 2022